PEACE-3 Videos

REVIEW UroToday

PEACE-3 Videos

Search

PEACE 3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad Details In this conversation, Fred Saad discusses the PEACE-3 trial results. The study compares enzalutamide plus radium-223 versus enzalutamide alone in metastatic castration-resistant prostate cancer patients with bone metastases. Dr. Saad discusses the trial's design, highlighting significant improvements in radiographic progression-free survival and overall survival with the combination therapy. They...
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal Details Oliver Sartor interviews Bertrand Tombal about the PEACE-3 trial. The study investigates the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer. Dr. Tombal discusses the trial design, results, and implications. The study demonstrates significant improvements in radiographic progression-free survival an...
Supporting Patients Receiving Radium-223 for mCRPC - Fred Saad Details Fred Saad and Alicia Morgans discuss the management of patients who are receiving a bone supportive agent plus radium-223 in metastatic prostate cancer and the benefit in reduction of bone complications. Patients with prostate cancer who had bone fractures had a reduced survival rate. Doing everything clinicians can to reduce the risk of fractures can not only improve quality of life but may actua...
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff Details In this conversation Tanya Dorff and Alicia Morgans discuss the guidance coming from the NCCN on the use of radium-223 in the metastatic castration-resistant prostate cancer setting, including choosing the right patient for this drug, factors to consider, and the timing of this therapy. As lines of therapy become more complicated with many castration-resistant drugs moving to the hormone-sensitive...
Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone Details Brenda Martone and Alicia Morgans discuss the positioning of radium-223 in the treatment of patients with bone-only mCRPC. Brenda emphasizes that radium-223 is approved for symptomatic bone-only disease and that this includes many symptoms including fatigue, loss of appetite, and others that are not limited to bone-related pain. This is approved in a broad population and needs to be considered in...
The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen Details In this conversation with Alicia Morgans, Silke Gillessen highlights the bone health analysis evaluating the combination of enzalutamide and radium or enzalutamide alone might affect bone health and fracture rate within patients with metastatic castration-resistant prostate cancer. At the 2021 ASCO meeting, Dr. Gillessen presented an updated safety analysis from the EORTC 1333 / PEACE III trial of...
Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal Details Bertrand Tombal discusses the ongoing PEACE III trial evaluating enzalutamide alone versus enzalutamide plus radium-223 post the ERA-223 data. The interim safety analysis was presented at ASCO and the data demonstrated that there was an increase fracture rate with the addition of radium-223 to enzalutamide prior to mandating the use of bone protecting agents. Pathological and non-pathological frac...